drugset / Trial / NCT06294548
A Study of Valemetostat Tosylate (DS-3201b) With Atezolizumab and Bevacizumab in HCC
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a phase Ib/II, dose escalation and dose expansion study of valemetostat (DS-3201) with atezolizumab and bevacizumab in patients advanced Hepatocellular carcinoma (HCC) who did not receive prior systemic therapy for advanced HCC.
Timeline
- Start
- 2025-07-29
- Primary completion
- 2028-01-30
- Completion
- 2028-08-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Valemetostat | Small molecule | 150 mg | Oral |
| Background | Atezolizumab | Monoclonal antibody | 1200 mg | Intravenous |
| Background | Bevacizumab | Monoclonal antibody | 15 mg/kg | Intravenous |